Iona Wallace

Iona Wallace

Auto-generated profile, based on publicly available information

Iona Wallace

Medical Research Council Protein Phosphorylation and Ubiquitylation Unit, School of Life Sciences, University of Dundee, Dundee, UK

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 December 2023 in Nature Communications
Verified
Journal Article
Open access
PDF file
IWIona Wallace
Iona Wallace
KBKheewoong Baek
Kheewoong Baek
JPJ. Rajan Prabu
J. Rajan Prabu
RVRonnald Vollrath
Ronnald Vollrath
SGSusanne von Gronau
Susanne von Gronau
KSKirby N. Swatek
Kirby N. Swatek
The attachment of the ubiquitin-like protein ISG15 to substrates by specific E1-E2-E3 enzymes is a well-established signalling mechanism of the innate immune response. Here, we present a 3.45 Å cryo-EM structure of a chemically trapped UBE1L-UBE2L6 complex bound to activated ISG15. This structure reveals the details of the first steps of ISG15 recognition and UBE2L6 recruitment by UBE1L (also known as UBA7). Taking advantage of viral effector proteins from severe acute respiratory coronavirus 2 (SARS-CoV-2) and influenza B virus (IBV), we validate the structure and confirm the importance of the ISG15 C-terminal ubiquitin-like domain in the adenylation reaction. Moreover, biochemical characterization of the UBE1L-ISG15 and UBE1L-UBE2L6 interactions enables the design of ISG15 and UBE2L6 mutants with altered selectively for the ISG15 and ubiquitin conjugation pathways. Together, our study helps to define the molecular basis of these interactions and the specificity determinants that ensure the fidelity of ISG15 signalling during the antiviral response.

18 July 2023 in Toxicological Sciences
Verified
Journal Article
Closed access
PDF file
WSWilliam Stebbeds
William Stebbeds
KRKavita Raniga
Kavita Raniga
DSDavid Standing
David Standing
IWIona Wallace
Iona Wallace
JBJames Bayliss
James Bayliss
JFJo Francis
Jo Francis
Cardiovascular toxicity is an important cause of drug failures in the later stages of drug development, early clinical safety assessment and even post-market withdrawals. Early-stage in vitro assessment of potential cardiovascular liabilities in the pharmaceutical industry involves assessment of interactions with cardiac ion channels, as well as induced pluripotent stem cell derived cardiomyocyte based functional assays, such as calcium flux and, multi-electrode-array assays. These methods are appropriate for the identification of acute functional cardiotoxicity but structural cardiotoxicity, which manifests effects after chronic exposure, is often only captured in vivo. CardioMotion is a novel, label-free, high throughput, in vitro assay and analysis pipeline which records and assesses the spontaneous beating of cardiomyocytes and identifies compounds which impact beating. This is achieved through the acquisition of brightfield images at a high framerate, combined with an optical flow-based python analysis pipeline which transforms the images into waveform data which are then parameterized. Validation of this assay with a large dataset showed that cardioactive compounds with diverse known direct functional and structural mechanisms-of-action on cardiomyocytes are identified (sensitivity = 72.9%), importantly, known structural cardiotoxins also disrupt cardiomyocyte beating (sensitivity = 86%) in this method. Furthermore, the CardioMotion method presents a high specificity of 82.5%. Impact Statement: CardioMotion enables the high throughput identification of small molecule compounds with potential cardiac liabilities, including structural cardiovascular toxicants, with high sensitivity and specificity based solely on the effect of compounds on the spontaneous beating of iPSc derived cardiomyocytes.

21 July 2023 in bioRxiv
Verified
Preprint
Open access
PDF file
ACAnne Clancy
Anne Clancy
EREmma V. Rusilowicz-Jones
Emma V. Rusilowicz-Jones
IWIona Wallace
Iona Wallace
KSKirby N. Swatek
Kirby N. Swatek
SUSylvie Urbé
Sylvie Urbé
MCMichael J. Clague
Michael J. Clague
Type 1 interferon stimulation highly up-regulates all elements of a ubiquitin-like conjugation system that leads to ISGylation of target proteins. An ISG15-specific member of the deubiquitylase family, USP18, is up-regulated in a co-ordinated manner. USP18 can also provide a negative feedback by inhibiting JAK-STAT signaling through protein interactions independently of DUB activity. Here, we provide an acute example of this phenomenon, whereby the early expression of USP18, post-interferon treatment of HCT116 colon cancer cells is sufficient to fully suppress the expression of the ISG15 E1 enzyme, UBA7. Stimulation of lung adenocarcinoma A549 cells with interferon reduces their growth rate but they remain viable. In contrast, A549 USP18 knock-out cells show similar growth characteristics under basal conditions, but upon interferon stimulation a profound inhibition of cell growth is observed. We show that this contingency on USP18 is independent of ISGylation, suggesting non catalytic functions are required for viability. We also demonstrate that global deISGylation kinetics are very slow compared with deubiquitylation. This is not influenced by USP18 expression, suggesting that enhanced ISGylation in USP18 KO cells reflects increased conjugating activity.